286 related articles for article (PubMed ID: 30401713)
1. Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.
Elahi-Gedwillo KY; Carlson M; Zettervall J; Provenzano PP
Cancer Res; 2019 Jan; 79(2):372-386. PubMed ID: 30401713
[TBL] [Abstract][Full Text] [Related]
2. T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
Li D; Schaub N; Guerin TM; Bapiro TE; Richards FM; Chen V; Talsania K; Kumar P; Gilbert DJ; Schlomer JJ; Kim SJ; Sorber R; Teper Y; Bautista W; Palena C; Ock CY; Jodrell DI; Pate N; Mehta M; Zhao Y; Kozlov S; Rudloff U
Mol Cancer Ther; 2021 Oct; 20(10):1926-1940. PubMed ID: 34376576
[TBL] [Abstract][Full Text] [Related]
3. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.
Blair AB; Kim VM; Muth ST; Saung MT; Lokker N; Blouw B; Armstrong TD; Jaffee EM; Tsujikawa T; Coussens LM; He J; Burkhart RA; Wolfgang CL; Zheng L
Clin Cancer Res; 2019 Sep; 25(17):5351-5363. PubMed ID: 31186314
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.
Jiang H; Torphy RJ; Steiger K; Hongo H; Ritchie AJ; Kriegsmann M; Horst D; Umetsu SE; Joseph NM; McGregor K; Pishvaian MJ; Blais EM; Lu B; Li M; Hollingsworth M; Stashko C; Volmar K; Yeh JJ; Weaver VM; Wang ZJ; Tempero MA; Weichert W; Collisson EA
J Clin Invest; 2020 Sep; 130(9):4704-4709. PubMed ID: 32749238
[TBL] [Abstract][Full Text] [Related]
6. Stromal biology and therapy in pancreatic cancer.
Neesse A; Michl P; Frese KK; Feig C; Cook N; Jacobetz MA; Lolkema MP; Buchholz M; Olive KP; Gress TM; Tuveson DA
Gut; 2011 Jun; 60(6):861-8. PubMed ID: 20966025
[TBL] [Abstract][Full Text] [Related]
7. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract][Full Text] [Related]
8. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
[TBL] [Abstract][Full Text] [Related]
9. Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease.
Filippini D; Agosto S; Delfino P; Simbolo M; Piro G; Rusev B; Veghini L; Cantù C; Lupo F; Ugel S; De Sanctis F; Bronte V; Milella M; Tortora G; Scarpa A; Carbone C; Corbo V
Sci Rep; 2019 Aug; 9(1):12286. PubMed ID: 31439856
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
[TBL] [Abstract][Full Text] [Related]
12. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer.
Goehrig D; Nigri J; Samain R; Wu Z; Cappello P; Gabiane G; Zhang X; Zhao Y; Kim IS; Chanal M; Curto R; Hervieu V; de La Fouchardière C; Novelli F; Milani P; Tomasini R; Bousquet C; Bertolino P; Hennino A
Gut; 2019 Apr; 68(4):693-707. PubMed ID: 30415234
[TBL] [Abstract][Full Text] [Related]
13. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
14. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Beatty GL; Chiorean EG; Fishman MP; Saboury B; Teitelbaum UR; Sun W; Huhn RD; Song W; Li D; Sharp LL; Torigian DA; O'Dwyer PJ; Vonderheide RH
Science; 2011 Mar; 331(6024):1612-6. PubMed ID: 21436454
[TBL] [Abstract][Full Text] [Related]
15. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.
Fearon DT
Cancer Immunol Res; 2014 Mar; 2(3):187-93. PubMed ID: 24778314
[TBL] [Abstract][Full Text] [Related]
16. The pancreas cancer microenvironment.
Feig C; Gopinathan A; Neesse A; Chan DS; Cook N; Tuveson DA
Clin Cancer Res; 2012 Aug; 18(16):4266-76. PubMed ID: 22896693
[TBL] [Abstract][Full Text] [Related]
17. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
Lafaro KJ; Melstrom LG
Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages.
Samain R; Brunel A; Douché T; Fanjul M; Cassant-Sourdy S; Rochotte J; Cros J; Neuzillet C; Raffenne J; Duluc C; Perraud A; Nigri J; Gigoux V; Bieche I; Ponzo M; Carpentier G; Cascone I; Tomasini R; Schmid HA; Mathonnet M; Nicolle R; Bousquet MP; Martineau Y; Pyronnet S; Jean C; Bousquet C
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1405-1436. PubMed ID: 33482394
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
[TBL] [Abstract][Full Text] [Related]
20. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
